Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01593605 · ClinicalTrials.gov registry record · NA
Resveratrol-Leucine Metabolite Synergy in Pre-diabetes
A NA study, sponsored by Vanderbilt University.
- Completed
- Registry status
- NA
- Development phase
- 36
- Enrollment target
NCT01593605: Completed NA study, sponsored by Vanderbilt University.
NCT01593605 is a NA study that has completed, run by Vanderbilt University. The registered enrollment target is 36 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01593605, a NA study, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
Study Summary
The study will evaluate the effects of resveratrol/leucine and resveratrol/HMB for their ability to control glucose levels in persons without diabetes but with impaired fasting glucose. Secondary assessments will examine the effect of these nutritional supplements versus placebo on inflammation, fasting lipids, HbA1C, and fructosamine, longer term metabolic markers of risk in diabetes.
Primary Outcome
We will evaluate the effects of resveratrol/leucine and resveratrol/HMB for their ability to control glucose levels in persons without diabetes but with impaired fasting glucose
Interventions
- OTHER Placebo treatment
- DIETARY_SUPPLEMENT Resveratrol
- DIETARY_SUPPLEMENT resveratrol /HMB
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2012-02 |
| Est. Completion | 2013-06 |
| Phase | NA |
What the finished NCT01593605 record still lists
NCT01593605 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo treatment is the first listed.
NCT01593605 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01593605 about?
NCT01593605 is a clinical study titled "Resveratrol-Leucine Metabolite Synergy in Pre-diabetes". The study will evaluate the effects of resveratrol/leucine and resveratrol/HMB for their ability to control glucose levels in persons without diabetes but with impaired fasting glucose. Secondary assessments will examine the effect of these nutritional supplements versus placebo on inflammation, fas...
What is the current status of trial NCT01593605?
This trial is currently completed. It is a NA study. The enrollment target is 36 participants. The study started on 2012-02. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01593605?
The interventions under investigation include: Placebo treatment (OTHER), Resveratrol (DIETARY_SUPPLEMENT), resveratrol /HMB (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01593605?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01593605's enrollment target sits among peer trials
36 1541st of 2000 higher than 437 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia